Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression

Journal of Psychiatric Research

Volumn 48, Issue 1, 2014, Pages 1-12

  Haque, Shadabul ^a   Md, Shadab ^a   Sahni, Jasjeet Kaur ^a   Ali, Javed ^a   Baboota, Sanjula ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Alginate nanoparticles; Depression; Forced swim test; Pharmacokinetic study; Venlafaxine

Indexed keywords

ALGINIC ACID; NANOPARTICLE; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD; BRAIN; CLIMBING; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; FORCED SWIMMING TEST; IMMOBILITY; IN VIVO STUDY; LOCOMOTION; NONHUMAN; NOSE; NOSE MUCOSA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT;

ALGINATE NANOPARTICLES; DEPRESSION; FORCED SWIM TEST; PHARMACOKINETIC STUDY; VENLAFAXINE;

ADMINISTRATION, INTRANASAL; ALGINATES; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CYCLOHEXANOLS; DEPRESSION; DISEASE MODELS, ANIMAL; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; MALE; MOTOR ACTIVITY; NANOPARTICLES; NASAL MUCOSA; PHARMACOKINETICS; RATS; RATS, WISTAR; SWIMMING; TIME FACTORS;

EID: 84888433752     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.10.011     Document Type: Article

References (58)

1. Ahmad Z., Pandey R., Sharma S., Khuller G.K. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. The Indian Journal of Chest Diseases & Allied Sciences 2006, 48:171-176.
2. Al-Ghananeem A.M., Saeed H., Florence R., Yokel R.A., Malkawi A.H. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. Journal of Drug Targeting 2010, 18:381-388.
3. Ali J., Ali M., Baboota S. Potential of nanoparticulate drug delivery systems by intranasal administration. Current Pharmceutical Design 2010, 10:1644-1653.
4. Bachmeier C.J., Beaulieu-Abdelahad D., Ganey N.J., Mullan M.J., Levin G.M. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 2011, 32:233-244.
5. Balin B.J., Broadwell R.D., Salcman M., el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. JComp Neurol 1986, 251:260-280.
6. Barton E.D., Colwell C.B., Wolfe T., Fosnocht D., Gravitz C., Bryan T., et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. The Journal of Emergency Medicine 2005, 29:265-271.
7. Broadwell R.D., Balin B.J. Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase invivo. JComp Neurol 1985, 242:632-650.
8. Castagné V., Moser P., Roux S., Porsolt R.D. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Current Protocols in Neuroscience 2011, 4, [Chapter 8: Unit 8.10A].
9. Chenite A., Gori S., Shive M., Desrosiers E., Buschmann D. Monolithic gelation of chitosan solutions via enzymatic hydrolysis of urea. Carbohydr Polym 2006, 64:419-424.
10. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
11. Cryan J.F., Page M.E., Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 2005, 182:335-344.
12. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. JPharm Sci 2010, 99:1654-1673.
13. Djupesland PG, Hafner R. Bi-directional nasal drug delivery. Innovations in Pharmaceutical Technology. (accessed 18.09.13). http://www.optinose.com.
14. Fazil M., Md S., Haque S., Jha M., Baboota S., Sahni J.K., et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012, 47:6-15.
15. Flens M.J., Zaman G.J.R., van der Valk P., Lzquierdo M.A., Schroeijers A.B., Scheffer G.L., et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996, 148:1237-1247.
16. Fernandez-Urrusuno R., Romani D., Calvo P. Development of a freeze dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. STP Pharma Sciences 1999, 5:429-436.
17. Greden J.F. The burden of recurrent depression: causes, consequences and future prospects. JClin Psychiatry 2001, 62:5-9.
18. Gross E.A., Swenberg J.A., Fields S., Popp J.A. Comparative morphometry of the nasal cavity in rats and mice. JAnat 1982, 135:83-88.
19. Haque S., Md S., Alam M.I., Sahni J.K., Ali J., Baboota S. Nanostructure based drug delivery systems for brain targeting. Drug Dev Ind Pharm 2012, 38:387-411.
20. Hermann D.M., Bassetti C.L. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol Sci 2007, 28:128-134.
21. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?. JPharm Sci 2007, 96:473-483.
22. Jansson B., Bjork E. Visualization of invivo olfactory uptake and transfer using fluorescein dextran. Journal of Drug Targeting 2002, 10:379-386.
23. Khan S., Patil K., Bobade N., Yeole P., Gaikwad R. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. Journal of Drug Targeting 2010, 18:223-234.
24. Khan S., Patil K., Yeole P., Gaikwad R. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. JPharm Pharmacol 2009, 61:669-675.
25. Kilts C.D. Potential new drug delivery system for antidepressants: an overview. JClin Psychiatry 2003, 64:31-33.
26. Kircanski K., Joormann J., Gotlib I.H. Cognitive aspects of depression. Wiley Interdisciplinary Reviews: Cognitive Science 2012, 3:301-313.
27. Kitada Y., Miyauchi T., Satoh A., Satoh S. Effetcs of antidepressants in rat forced swimming test. Eur J Pharmacol 1981, 72:145-152.
28. Kumar M., Misra A., Babbar A.K., Mishra A.K., Mishra P., Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. International Journal of Pharmaceutics 2008, 358:285-291.
29. Kumar M., Misra A., Mishra A.K., Mishra P., Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. Journal of Drug Targeting 2008, 16:806-814.
30. de Lange E.C., Bock G.D., Shinkel A.H., Boer A.G., Breimer D.D. BBB transport using MDR 1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of Rhodamine-123. Pharmaceutical Research 1998, 15:1657-1665.
31. Lenox R.H., Frazer A. Mechanism of action of antidepressants and mood stabilizers. Neuropsychopharmacology: the fifth generation of progress 2008, 1138-1156. Lippincott Williams and Wilkins, Philadelphia. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
32. Liu H.J., Li P., Wei Q. Magnetic N-succinyl chitosan/alginate beads for carbamazepine delivery. Drug Dev Ind Pharm 2010, 36:1286-1294.
33. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews Neuroscience 2005, 6:591-602.
34. Md S., Khan R.A., Mustafa G., Chuttani K., Baboota S., Sahni J.K., et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 2012, 48:393-405.
35. Motwani S.K., Chopra S., Talegaonkar S., Kohli K., Ahmad F.J., Khar R.K. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and invitro characterisation. Eur J Pharm Biopharm 2008, 68:513-525.
36. Muller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Delivery Rev 2001, 47:3-19.
37. Murray C., Lopez A. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996, 274:740-743.
38. Nutt D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. JClin Psychiatry 2008, 69:4-7.
39. Pires A., Fortuna A., Alves G. Intranasal drug delivery: how, why and what for. Journal of Pharmacy and Pharmaceutical Sciences 2009, 12:288-311.
40. Porsolt R.D., Bertin A., Jalfre M. "Behavioral despair" in rats and mice: strain differences and the effect of imipramine. Eur J Pharmacol 1978, 51:291-294.
41. Pund S., Rasve G., Borade G. Exvivo permeation characteristics of venlafaxine through sheep nasal mucosa. Eur J Pharm Sci 2013, 48:195-201.
42. Rahman A., Patel V., Maselko J., Kirkwood B. The neglected 'm' in MCH programmes-why mental health of mothers is important for child nutrition. Trop Med Int Health 2008, 13:579-583.
43. Rajaonarivony M., Vauthier C., Couarraze G., Puisieux F., Couvreur P. Development of a new drug carrier made from alginate. JPharm Sci 1993, 82:912-917.
44. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. JNeurol Neurosurg Psychiatry 2005, 76:148-152.
45. Sahni J.K., Doggui S., Ali J., Baboota S., Dao L., Ramassamy C. Neurotherapeutic applications of NPs in Alzheimer's disease. JControl Release 2011, 152:208-231.
46. Sarmento B., Ferreira D., Veig F., Ribeiro A. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym 2006, 66:1-7.
47. Sintov A.C., Levy H.V., Botner S. Systemic delivery of insulin via the nasal route using a new microemulsion system: invitro and invivo studies. JControl Release 2010, 148:168-176.
48. Smith J.M., Dornish M. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 2005, 26:3269-3276.
49. Stahl S.M., Grady M.M., Moret C., Briley M. SNRIs: their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants. CNS Spectrum 2005, 10:732-747.
50. Sweatman T.W., Seshadri R., Israel M. Metabolism and elimination of Rhodamine-123 in the rat. Cancer Chemother Pharmacol 1990, 27:205-210.
51. Thorne R.G., Frey W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001, 40:907-946.
52. Thorne R.G., Pronk G.J., Padmanavan V., Frey W.H. Delivery of insulin like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
53. Tosi G., Costantino L., Rivasi F., Ruozi B., Leo E., Vergoni A.V., et al. Targeting the central nervous system: Invivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. JControl Release 2007, 122:1-9.
54. Troy S.M., Parekar V.D., Fruncillo R.J., Chiang S.T. The pharmacokinetics of venlafaxine when given in a twice daily regimen. JClin Pharmacol 1995, 35:404-409.
55. Vergoni A.V., Tosi G., Tacchi R., Vandelli M.A., Bertolini A., Costantino L. Nanoparticles as drug delivery agents specific for CNS: invivo biodistribution. Nanomedicine: Nanotechnology, Biology and Medicine 2009, 5:369-377.
56. Vllasaliu D., Exposito-Harris R., Heras A., Casettari L., Garnett M., Illum L., et al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. International Journal of Pharmaceutics 2010, 400:183-193.
57. Wilson A.D., Howell C., Waring W.S. Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. The Journal of Toxicological Sciences 2007, 32:97-101.
58. Zahoor A., Sharma S., Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005, 26:298-303.